Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-aging intradermal treatment with PDRN and growth factors for facial skin aging
RBR-4g8m6y7Phase 3Recruiting
- Sponsor
- Universidade Estadual de Montes Claros
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of polideoxirybonucleotide, avotermin, epidermal growth factor and trafermin in cutaneous aging (2 arms), sponsored by Universidade Estadual de Montes Claros. Primary endpoints: Molecular and cellular changes in skin biopsies, Safety and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
polideoxirybonucleotideavoterminepidermal growth factortrafermin
03
Conditions
cutaneous aging
Beyond the preview
Go deeper on RBR-4g8m6y7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4g8m6y7.